CorMedix Inc (CRMD)

[Investor100]

Good write up @ H.C Wainwright

Looking forward to more news in the weeks, months ahead!


We believe that submission of the interim data to the FDA could occur within the coming weeks. Given the significant unmet need in treating CRBSIs, which result in death for 20% or more of the patients who develop them, we feel that the FDA could prove amenable to considering fast-tracked submission of Neutrolin for review and accelerated approval for the product in the U.S. As such, therefore, we think there is a possibility now for Neutrolin to be filed before the end of this year and to be approved in 2019, vs. our original assumption that the drug would not enter the U.S. market prior to 2020. Furthermore, the news of the clear efficacy signal in the LOCK-IT-100 study could meaningfully accelerate ex-U.S. sales of the product. We reiterate our Buy rating and raise our price target to $3.00 from $2.00 per share on CRMD.”


http://www.analystratings.com/articles/h-c-wainwright-sticks-to-their-buy-rating-for-cormedix-inc/

Investor 100